<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759872</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-2020-0768</org_study_id>
    <nct_id>NCT04759872</nct_id>
  </id_info>
  <brief_title>Insulin and Muscle Fat Metabolism</brief_title>
  <official_title>Insulin and Muscle Fat Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our objective in this study is to identify the extent to which insulin drives the&#xD;
      accumulation of lipids in skeletal muscle of humans. We will test the hypothesis that 4-hours&#xD;
      of mild hyperinsulinemia will result in significant muscle lipid accumulation and that such&#xD;
      effects will be similar in lean and overweight/obese humans.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will be asked to complete 1 screening visit to determine eligibility.&#xD;
If participants remain eligible, they will be asked to complete 1 metabolic study visit.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in skeletal muscle lipid content during hyperinsulinemia compared with basal resting conditions</measure>
    <time_frame>Muscle samples will be collected in basal and hyperinsulinemic conditions separated by ~4.5 hours during the metabolic study visit</time_frame>
    <description>Liquid chromatography tandem mass spectrometry (targeted lipidomics) will be used to assess species-level changes in skeletal muscle lipid content in biopsy samples collected before and after the insulin infusion to induce mild hyperinsulinemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in skeletal muscle mitochondrial oxidative capacity during hyperinsulinemia compared with basal resting conditions</measure>
    <time_frame>Muscle samples will be collected in basal and hyperinsulinemic conditions separated by ~4.5 hours during the metabolic study visit</time_frame>
    <description>High-resolution respirometry will be used to assess changes in skeletal muscle mitochondrial oxidative capacity in biopsy samples collected before and after the insulin infusion to induce mild hyperinsulinemia.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Overweight and Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Metabolic Disease</condition>
  <condition>Mitochondrial Metabolism</condition>
  <condition>Sedentary Lifestyle</condition>
  <arm_group>
    <arm_group_label>Metabolic Study Visit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete a study visit for metabolic phenotyping and determination of the impact of hyperinsulinemia on outcomes of interest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperinsulinemic-euglycemic Clamp</intervention_name>
    <description>Participants will be administered a constant-rate insulin infusion (to induce mild hyperinsulinemia), with an infusion of dextrose to maintain blood glucose concentration (to maintain euglycemia).</description>
    <arm_group_label>Metabolic Study Visit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 30-55 years&#xD;
&#xD;
          -  Body mass index (BMI) 18-45 kg/m2&#xD;
&#xD;
          -  Sedentary (&lt;1 hour of planned exercise per week)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Regular exercise (&gt;1 hour of planned exercise per week)&#xD;
&#xD;
          -  Smoking, tobacco or nicotine use within the last 1-year&#xD;
&#xD;
          -  Fasting glucose &gt;126mg/dL&#xD;
&#xD;
          -  Hypertension (systolic pressure &gt;140 mmHg or diastolic pressure &gt;90 mmHg)&#xD;
&#xD;
          -  Chronic metabolic or cardiovascular health conditions&#xD;
&#xD;
          -  Pregnant, nursing, irregular menses or post-menopausal&#xD;
&#xD;
          -  Lidocaine allergy&#xD;
&#xD;
          -  Certain medications&#xD;
&#xD;
          -  Diminished capacity for consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean A Newsom, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew M Robinson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sean A Newsom, Ph.D.</last_name>
    <phone>5417371126</phone>
    <email>sean.newsom@oregonstate.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthew M Robinson, Ph.D.</last_name>
    <phone>5417371988</phone>
    <email>matthew.robinson@oregonstate.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon State University</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean A Newsom, Ph.D.</last_name>
      <phone>541-737-1613</phone>
      <email>sean.newsom@oregonstate.edu</email>
    </contact>
    <contact_backup>
      <last_name>Matthew M Robinson, Ph.D.</last_name>
      <phone>5417371126</phone>
      <email>matthew.robinson@oregonstate.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

